LivingGLP1
Study S001761

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

ClinicalTrials.gov record

Registration

Registration
NCT06426446
Acronym
TELE-SEMA
Study type
INTERVENTIONAL
Masking
NONE
Status
UNKNOWN
Enrollment
80
Start
2024-06-01
Primary completion
2025-06-01
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Conditions
Obesity
Interventions
DEVICE:Withings Body Comp Pro
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • The relative difference in weight loss achieved at 6 months of treatment at the maximum tolerated dose ((weight after 6 months of treatment at the maximum tolerated dose - baseline weight) / baseline weight) [6 months]

Linked records (8)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0021078Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
Wharton S, Obesity (Silver Spring, Md.)
2023Randomized trialPMID 36655300DOIregistry reference BACKGROUND:36655300
R0021791Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Kosiborod MN, Diabetes, obesity & metabolism
2023Randomized trialPMID 36200477DOIregistry reference BACKGROUND:36200477
R0008328Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale JF, BMJ open diabetes research & care
2022Nonrandomized studyPMID 35383100DOIregistry reference BACKGROUND:35383100
R0013698Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
Di Loreto C, Diabetes therapy : research, treatment and education of diabetes and related disorders
2022Nonrandomized studyPMID 35230650DOIregistry reference BACKGROUND:35230650
R0013888Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
Garcia de Lucas MD, Frontiers in endocrinology
2022Nonrandomized studyPMID 36187123DOIregistry reference BACKGROUND:36187123
R0023390Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
Rajamand Ekberg N, Primary care diabetes
2021Nonrandomized studyPMID 34183269DOIregistry reference BACKGROUND:34183269
R0023399Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, The New England journal of medicine
2021Randomized trialPMID 33567185DOIregistry reference BACKGROUND:33567185
R0019740Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, JCI insight
2020PreclinicalPMID 32213703DOIregistry reference BACKGROUND:32213703